CGTLive’s Weekly Rewind – January 27, 2023

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

With confidence building, numerous cell and gene therapies will likely go before the FDA and other global regulatory agencies this year, in addition to key data readouts.

Simeone discussed the progress and challenges seen so far in the BASECAMP-1 observational study.

The DGX-A01 study met its primary safety and efficacy endpoints in its highest dose cohort of IDCT.

The associate professor of medicine at University of Pennsylvania discussed new data from the BENEGENE-2 study of fidanacogeneelaparvovec.

Iovance is on track to complete its rolling BLA submission for lifileucel in the post-anti-PD1 melanoma indication in the first quarter of 2023.